Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

University of Washington

Status

Enrolling

Conditions

Myeloid Neoplasm Post Cytotoxic Therapy

Recurrent Primary Peritoneal Carcinoma

Recurrent Malignant Solid Neoplasm

Clonal Cytopenia of Undetermined Significance

Recurrent Fallopian Tube Carcinoma

Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder

Ovarian Carcinoma

Idiopathic Cytopenia of Undetermined Significance

Recurrent Ovarian Carcinoma

Clonal Hematopoiesis

Treatments

Other: Non-Interventional Study

Study type

Observational

Funder types

Other

NIH

Identifiers

NCT06295965

FHIRB0020162 (Other Identifier)

R01CA272594 (U.S. NIH Grant/Contract)

NCI-2023-10315 (Registry Identifier)

RG1123813

Details and patient eligibility

About

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

Full description

OUTLINE: This is an observational study.

Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.

Enrollment

2,000 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:
- Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy

Subjects who have or have had a solid tumor diagnosis and any of the following:
- At least 4 months of exposure to a PARP inhibitor
- Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm

Exclusion criteria